Psilera
psilera.com
Actively hiring
Drug Discovery
Health Care
Biotechnology
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$11.3M
2 rounds on record
Latest round
$8.8M
Seed · May 2026 · 4 mo ago
Team
11-50
employees, estimated range
The money's age
Fresh money
4 months since the last round · not hiring
Momentum
20/100
fresh money
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 28
Raised a round Seed $8.8M
Jul 1, 2021
Raised a round Venture round $2.5M · SEC Form D
2021
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Seed | May 2026 | $8.8M | — | morningstar.com |
| Venture round | Jul 2021 | $2.5M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Psilera Inc | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Jacqueline SalmExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
backs Treeline Biosciences
backs Treeline Biosciences
Similar startupsby what they do, their industry and backers
Autobahn aims to improve life health for people affected by CNS disorders by driving the regenerative power of the human body.
0 About Us AAX Biotech AB is a research-driven biotech company with proprietary technologies that solve unmet needs in the development of…
Transforming the Future of Neuropsychiatry. Draig Therapeutics is developing transformative, best-in-class neuropsychiatric therapies to…
Antibodies Transformed. A revolutionary class of computationally designed biologics engineered to unlock challenging pathways and better…
We navigate evolutionary data to translate extreme biological adaptations into first-in-class medicines. Learn more about our process.
Treeline Biosciences is a biotechnology company developing small-molecule medicines for cancer and immune diseases.
Overview
Psilera is a biotechnology company developing groundbreaking first-in-class treatments for neurological disorders by creating a new class of next-generation neuroplastogens.
People
Jacqueline Salm
Executive Officer
Scott Rairigh
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Tampa
United States
HQ
10-50 est. staff